Latest data from the Hong Kong Stock Exchange reveals that on November 26, a shareholder of REMEGEN (09995) transferred shares from BNP Paribas to HSBC, with the transaction valued at HK$896 million, representing a 5.29% stake.
CCB International recently issued a research report, raising REMEGEN's target price by 9% from HK$110 to HK$120 while maintaining an "Outperform" rating. The report indicated that CCB International largely kept its revenue forecasts for REMEGEN unchanged for 2025, 2026, and 2027, projecting total revenues of RMB2.8 billion, RMB3.4 billion, and RMB4.6 billion, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments